• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Navidea Biopharmaceuticals

Navidea names two appointments to its board of directors

October 14, 2021 By Sean Whooley

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors. Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea’s board, effective Oct. 7, each with a three-year term ending concurrently with the company’s 2024 annual stockholders meeting. According to a news release, Farb-Horch, a veteran of over three […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Personnel, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals, Personnel, Personnel Moves

Navidea Biopharmaceuticals makes board of directors changes

September 17, 2021 By Sean Whooley

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors. Dublin, Ohio–based Navidea ‘s chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions, effective immediately. The board appointed Alexander L. Cappello and John K. Scott, Jr., both existing members […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals, Personnel, Personnel Moves

Navidea receives patent for dextran-based drug delivery vehicles

May 19, 2021 By Sean Whooley

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it received a patent for its dextran-based drug delivery vehicles. The U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,007,272 entitled “Compounds and Methods for Diagnosis and Treatment of Viral Infections,” with protection to October 7, 2037, according to a news release. Dublin, Ohio-based Navidea’s patent protects the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals

Navidea enters into $5M private placement

March 2, 2021 By Sean Whooley

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it entered into a private placement worth $5 million. Dublin, Ohio-based Navidea’s agreement comes with its largest shareholder, John K. Scott, Jr., for the purchase of $5 million in newly-designated Series E redeemable convertible preferred stock, according to a news release. Over the course of the next 18 months, the […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals

Navidea deals NA Lymphoseek rights to Cardinal Health in $310m deal

November 28, 2016 By Sarah Faulkner

Navidea Biopharmaceuticals (NYSE:NAVB) said today that it inked a definitive asset purchase agreement with Cardinal Health (NYSE:CAH) for its Lymphoseek product. Dublin, Ohio-based Navidea said it’s due to receive $80 million at closing for the lymphatic mapping and lymph node biopsy product, plus the opportunity for $230 million in milestone payments through 2026. More than $20 […]

Filed Under: Diagnostics, Featured, Mergers & Acquisitions, Oncology, Wall Street Beat Tagged With: Cardinal Health, Navidea Biopharmaceuticals

Neoprobe executives plan stock sell-off if FDA green-lights Lymphoseek

September 23, 2011 By drugdelivery

Neoprobe

Neoprobe Corp. (NYSE Amex:NEOP) are prepping to sell off about 500,000 shares of stock should the company’s new drug application get the green light from the FDA.

Senior vice president & CFO Brent Larson, regulatory affairs & quality assurance VP Rodger Brown and former president & CEO David Bupp revealed plans to sell substantial portions of their stakes at various times over up to one year.

Filed Under: Drug-Device Combinations Tagged With: Navidea Biopharmaceuticals

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS